

# February 2025 Dashboard

## Letters of intent

*Increase access, improve consistency and reduce duplication*

Since the pCPA's inception, **638** negotiations have reached a letter of intent (LOI), including:



- **235** for oncology
- **64** for biosimilars
- **74** for expensive drugs for rare diseases (EDRD)

## Savings

*Lower drug costs*




pCPA activities saved jurisdictions an estimated **\$4.63B** in 2023-24.

- **\$3.72B** from brand- name drugs
- **\$914M** from generic drugs
- Since 2010, cumulative savings are estimated to be **\$24.0B**





## HTA and pCPA volumes

- 2024 saw a very high number of HTA recommendations, almost matching the record set in 2022.
- The pCPA hired additional staff to **increase its capacity** to start new negotiations, and engaged **98 files** in 2024.




## pCPA activity

- The number of files in consideration **fell below 20 files** for the first time in the post-COVID era, due in part to increased staffing.
- The pCPA is committed to further decreasing the queue over time.
- Active negotiations have significantly increased, with the pCPA negotiating more than 40 files between **September 15 and December 31, 2024**.



## pCPA timelines

- Median time under consideration, active negotiation time and total timelines have **improved between 2020 and 2024**.
- The typical total negotiation time was **8 months** from HTA recommendation to file completion.



\* Time under consideration and total timelines are only assessed for files arising from HTA recommendations, and excludes files that do not undergo negotiations. pCPA targets outlined in the brand process guidelines are approximately 2 months for file engagement, 4 months for active negotiations and 6 months combined.